Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.

Oncotarget - 6 Oct 2015

Rigoni Micol, Riganti Chiara, Vitale Candida, Griggio Valentina, Campia Ivana, Robino Marta, Foglietta Myriam, Castella Barbara, Sciancalepore Patrizia, Buondonno Ilaria, Drandi Daniela, Ladetto Marco, Boccadoro Mario, Massaia Massimo, Coscia Marta

Abstract excerpt

The immunoglobulin heavy-chain variable region (IGHV) mutational status is a strong determinant of remission duration in chronic lymphocytic leukemia (CLL). The aim of this work was to compare the multidrug resistance (MDR) signature of IGHV mutated and unmutated CLL cells, identifying biochemica...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Doxorubicin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple

Share to Hypoxia-Inducible Factor 1, alpha Subunit

Share to Immunoglobulin Heavy Chains

Share to Immunoglobulin Variable Region

Share to Simvastatin

Share to Stromal Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 26284584
DOI: 10.18632/oncotarget.4006
PMCID: PMC4745766

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26284584-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.PMID 26284584Read ↗

ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.Semantic proximity Read ↗

Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management.Semantic proximity Read ↗

CaMKK2 Expression Correlates with High-Risk CLL Biology, and Pharmacologic Inhibition Is Associated with Reduced Leukemic Cell Survival and Nurse-like Cell Support In Vitro.Semantic proximity Read ↗

Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1)Semantic proximity Read ↗

Lipophilic statins antagonistically alter the major epithelial‐to‐mesenchymal transition signaling pathways in breast cancer stem–like cells via inhibition of the mevalonate pathwaySemantic proximity Read ↗

Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.Semantic proximity Read ↗

IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.Semantic proximity Read ↗

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemiaSemantic proximity Read ↗

AT-101 induces apoptosis in CLL B cells and overcomes stromal cell–mediated Mcl-1 induction and drug resistanceSemantic proximity Read ↗

Overcome Resistance in Doxorubicin-Adapted Hodgkin Lymphoma Cells With Acquired Multidrug Resistance and Improved Immunosuppressive AbilitiesSemantic proximity Read ↗

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.Semantic proximity Read ↗

Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.